

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM542344

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Cantor Fitzgerald Securities, as Administrative Agent		09/24/2019	General Partnership: NEW YORK
RECEIVING PARTY DATA			
Name:	Aegerion Pharmaceuticals, Inc.		
Street Address:	One Main Street, Suite 800		
City:	CAMBRIDGE		
State/Country:	MASSACHUSETTS		
Postal Code:	02142		
Entity Type:	Corporation: MASSACHUSETTS		
PROPERTY NUMBERS Total: 11			
Property Type	Number	Word Mark	
Registration Number:	4508190	JUXTAPID	
Registration Number:	4512713	JUXTAPID	
Registration Number:	5276666	LOWER	
Registration Number:	4589120	MYALEPT	
Registration Number:	4607022	MYALEPT	
Registration Number:	5237691	BYMYSIDE	
Registration Number:	5237690	BYMYSIDE	
Registration Number:	5381456	NOVELION THERAPEUTICS	
Registration Number:	5381517	NOVELION THERAPEUTICS	
Registration Number:	3300046	AEGERION	
Registration Number:	3977343	AEGERION PHARMACEUTICALS	
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	3129932652		
Email:	heather.poitras@lw.com		
Correspondent Name:	Heather Poitras		
Address Line 1:	330 North Wabash		

CH \$290.00 4508190

Address Line 2: Suite 2800
Address Line 4: Chicago, ILLINOIS 60611

ATTORNEY DOCKET NUMBER: 062219.0001 hp

NAME OF SUBMITTER: Heather Poitras

SIGNATURE: /hp/

DATE SIGNED: 09/24/2019

Total Attachments: 4

source=Cantor - Trademark Release_110964776_1_0#page1.tif
source=Cantor - Trademark Release_110964776_1_0#page2.tif
source=Cantor - Trademark Release_110964776_1_0#page3.tif
source=Cantor - Trademark Release_110964776_1_0#page4.tif

TRADEMARK RELEASE

THIS TRADEMARK RELEASE is made as of September 24, 2019, by Cantor Fitzgerald Securities, as Administrative Agent (in such capacity, the “Grantee”) for certain lenders. Capitalized terms used but not defined herein shall have the same meanings assigned to such terms in the Security Agreement (as defined below).

W I T N E S S E T H:

WHEREAS, Aegerion Pharmaceuticals, Inc. (“Grantor”) and Grantee were parties to that certain Trademark Security Agreement dated as of November 8, 2018 (the “Security Agreement”) pursuant to which Grantor granted a security interest to Grantee in certain Trademarks and Trademark Collateral (as defined below) as security for certain obligations owing by Grantor to Grantee, including the Trademarks set forth on Schedule A hereto;

WHEREAS, the Security Agreement was recorded by the Trademark Division of the United States Patent and Trademark Office on November 8, 2018, at Reel 6478, Frame 0177;

WHEREAS, Grantor has requested that Grantee terminate and release its security interest in and liens on the Trademarks and Trademark Collateral and reassign any and all rights in the same to Grantor; and

WHEREAS, Grantor has satisfied and fulfilled all of its obligations to release the Grantee’s security interest in the Trademarks and Trademark Collateral.

NOW THEREFORE, for good and valuable consideration, receipt and sufficiency of which are hereby acknowledged:

1. Grantee hereby terminates, releases and discharges its continuing security interest in and liens on Grantor’s entire right, title and interest in and to and under the Trademarks, together with, among other things, the goodwill of business symbolized by the Trademarks and the applications and registrations thereof, and all proceeds thereof, including, without limitation, any and all causes of action which may exist by reason of infringement thereof and any and all damages arising from past, present and future violations thereof (all such items or types of property being herein collectively referred to as the “Trademark Collateral”):

2. Grantee hereby authorizes the Grantor, or the Grantor’s authorized representative(s), as the case may be, to record this Trademark Release with the United States Patent and Trademark Office and any other applicable governmental office or agency. The Grantee further authorizes and requests that any necessary United States government officer record this Trademark Release, it being understood that such recordation shall be at the Grantor’s sole expense.

3. Grantee shall take all further actions and provide to Grantor, its successors, assigns or other legal representatives, all such cooperation and assistance (including, without limitation, the execution and delivery of documents or other instruments) reasonably requested by Grantor to more fully and effectively effectuate the purposes of this Trademark Release, at Grantor’s sole expense, and without representation or warranty by Grantee.

4. The laws of the State of New York shall govern all matters arising out of, in connection with or relating to this Trademark Release, including, its validity, interpretation, construction, performance

and enforcement (including, any claims sounding in contract or tort law arising out of the subject matter hereof and any determinations with respect to post judgment interest).


6. This Trademark Release may be executed in any number of counterparts and delivered by facsimile or otherwise electronically, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same document.


7. Cantor Fitzgerald Securities is entering into this Trademark Release solely in its capacity as Administrative Agent. The rights, privileges and immunities of the Administrative Agent set forth in the Credit Agreement and the Guarantee and Collateral Agreement shall be incorporated into this Trademark Release as though fully set forth herein.

[Signature Page Follows]

IN WITNESS WHEREOF, Grantee has caused this Trademark Release to be executed as of the day and year first above written.

CANTOR FITZGERALD SECURITIES, as
Administrative Agent

By: 
Name: James Buccola
Title: Head of Fixed Income



Signature Page to Trademark Release

(Aegon)

TRADEMARK
REEL: 006753 FRAME: 0675

SCHEDULE A

Owner/Applicant	Mark	Jurisdiction	Application No.	Registration No.	Status	Filing Date	Publication Date	Registration Date
Aegerion Pharmaceuticals, Inc.	JUXTAPID	US	85/980,934	4,508,190	Registered	12/14/2012		4/1/2014
Aegerion Pharmaceuticals, Inc.	JUXTAPID LOGO	US	85/981,114	4,512,713	Registered	2/22/2013		4/8/2014
Aegerion Pharmaceuticals, Inc.	LOWER	US	86/235,722	5,276,666	Registered	3/28/2014	9/15/2015	8/29/2017
Aegerion Pharmaceuticals, Inc.	MYALEPT	US	85/484,675	4,589,120	Registered	12/1/2011	5/15/2012	8/19/2014
Aegerion Pharmaceuticals, Inc.	MYALEPT LOGO	US	86/043,958	4,607,022	Registered	8/21/2013	1/14/2014	9/16/2014
Aegerion Pharmaceuticals, Inc.	BYMYSIDE	US	86/786,387	5,237,691	Registered	10/13/2015	9/20/2016	7/4/2017
Aegerion Pharmaceuticals, Inc.	BYMYSIDE LOGO	US	86/786,368	5,237,690	Registered	10/13/2015	9/20/2016	7/4/2017
Aegerion Pharmaceuticals, Inc.	NOVELION THERAPEUTICS	US	87/043,469	5,381,456	Registered	5/19/2016	4/25/2017	1/16/2018
Aegerion Pharmaceuticals, Inc.	NOVELION THERAPEUTICS (LOGO)	US	87/072,521	5,381,517	Registered	6/15/2016	3/21/2017	1/16/2018
Aegerion Pharmaceuticals, Inc.	AEGERION	US	78/906,083	3,300,046	Registered	6/12/2007	1/23/2007	9/25/2007
Aegerion Pharmaceuticals, Inc.	AEGERION PHARMACEUTICALS (STYLIZED)	US	85/162,494	3,977,343	Registered	10/27/2010	3/29/2011	6/14/2011

TRADEMARK